Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors

Histone deacetylase (HDAC) inhibitors, approved for the treatment of cutaneous T-cell lymphoma (CTCL), are non-selective agents associated with an unsatisfactory response and considerable side-effects. Targeting single HDAC isoforms is considered to provide novel therapeutic options. HDAC6 is overex...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobrowicz, Malgorzata, Slusarczyk, Aleksander, Domagala, Joanna, Dwojak, Michal, Ignatova, Desislava, Chang, Yun-Tsan, Iselin, Christoph, Miazek-Zapala, Nina, Marhelava, Katsiaryna, Guenova, Emmanuella, Winiarska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285804/
https://www.ncbi.nlm.nih.gov/pubmed/32565979
http://dx.doi.org/10.3892/ol.2020.11587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285804/
https://www.ncbi.nlm.nih.gov/pubmed/32565979
http://dx.doi.org/10.3892/ol.2020.11587

Ejemplares similares